

SynAct Pharma management and Chairman of the Board have acquired shares

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the CEO, CSO, CBO, and the Chairman of the Board have acquired shares in the company.

Specifically, the Chairman of the Board, Anders Kronborg has acquired 3,470 shares, the CEO Jeppe Øvlesen, CSO Thomas Jonassen, and CBO Mads Bjerregaard, have acquired 8,558 shares. Total of 12,028 shares.

"We are close to finalizing recruitment on our lead program in Rheumatoid Arthritis, and we are ready to initiate trial in viral infection. We are looking forward to an exciting 2026 with a strong team and upcoming key data. It is a pleasure to see the strong commitment in the management group and to have the support of our board," said CEO Jeppe Øvlesen.

The purchases were made on Nasdaq OMX Stockholm.

For further information, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[SynAct Pharma management and Chairman of the Board have acquired shares](#)